View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 15, 2022

Clene’s CNM-Au8 boosts survival in amyotrophic lateral sclerosis trial

CNM-Au8 was found to be well-tolerated without any significant safety findings observed in the trial.

Clene and its subsidiary Clene Nanomedicine have reported data from RESCUE-ALS long-term, open-label extension clinical trial, where CNM-Au8 substantially boosted survival in patients with amyotrophic lateral sclerosis (ALS).

An oral suspension of gold nanocrystals, CNM-Au8 was developed for restoring neuronal health and function by boosting energy production and usage.

The trial enrolled 45 participants who were randomised into a 1:1 ratio to receive 30mg CNM-Au8 or placebo daily for 36 weeks during the trial’s double-blind portion.

Subsequently, in the open-label portion, the subjects received treatment for up to 130 weeks from randomisation.

As of the data cutoff on 5 July this year, five deaths were reported in the group which was randomised to receive CNM-Au8 compared to 14 in the group initially randomised to receive placebo.

Due to inadequate mortality events, median survival from randomisation in the CNM-Au8 group was undefined versus 23.1 months in the placebo arm.

According to the unadjusted Kaplan-Meier survival assessments, a substantial survival benefit was demonstrated in subjects initially randomised to the CNM-Au8 treatment group compared to those who received a placebo initially, indicating a 70% decline in mortality risk.

Furthermore, CNM-Au8 was found to be well-tolerated without any significant safety findings observed during the long-term, open-label study period.

Clene president and CEO Rob Etherington said: “We are very pleased to see these results and the apparent survival benefit that our investigational drug, CNM-Au8, appears to provide to people living with ALS.

“At this point, we are awaiting top-line data from the HEALEY ALS Platform Trial, which focuses on endpoints measuring patient function, survival and breathing over a six-month period in a much larger cohort.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena